BioCardia, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
BioCardia, Inc. (BCDA) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $4.26 per share as of 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2023-05-10
- 2023-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $4.26.
- 2022-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $3.81.
- 2013-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $0.44.
- 2013-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $0.44.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value |
|---|---|
| 2023-03-31 | $4.26 10-Q · filed 2023-05-10 |
| 2022-09-30 | $3.81 10-Q · filed 2022-11-09 |
| 2013-12-31 | $0.44 10-Q · filed 2014-11-06 |
| 2013-09-30 | $0.44 10-Q · filed 2013-11-01 |
| 2013-06-30 | $0.44 10-Q · filed 2013-07-26 |
| 2013-03-31 | $0.44 10-Q · filed 2013-05-10 |
| 2012-12-31 | $0.44 10-K · filed 2013-03-22 |
| 2012-09-30 | $0.44 10-Q · filed 2012-11-08 |
| 2012-06-30 | $0.44 10-Q · filed 2012-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |